#8347 TRAF Antibody Sampler Kit
|TRAF1 (45D3) Rabbit mAb #4715||20 µl||WB, IP, IHC-P, IF-IC, F||H||Mk||50||Rabbit|
|TRAF2 (C192) Antibody #4724||20 µl||WB, IP||H, M, Mk||53||Rabbit|
|TRAF3 Antibody #4729||20 µl||WB||H, M, R, Mk||62||Rabbit|
|TRAF6 (D21G3) Rabbit mAb #8028||20 µl||WB, IP||H, Mk||60||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
†Species predicted to react based on 100% sequence homology.
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), IF-IC=Immunofluorescence (Immunocytochemistry), F=Flow Cytometry
Reactivity Key: H=Human, M=Mouse, Mk=Monkey, R=Rat
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from Raji and SR cells, using TRAF1 (45D3) Rabbit mAb.
Western blot analysis of extracts from Jurkat, 293, HeLa, C2C12, and NIH/3T3 cells, using TRAF2 (C192) Antibody.
Western blot analysis of extracts from COS-7 cells, untransfected (-) or transfected with human TRAF3 construct (+) using TRAF3 Antibody.
Western blot analysis of extracts from 293T cells, either mock transfected (-) or transfected with a cDNA expression construct encoding full-length human TRAF6 (+), using TRAF6 (D21G3) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human tonsil using TRAF1 (45D3) Rabbit mAb preincubated with a control peptide (left) or TRAF1 Blocking Peptide #1066 (right).
Western blot analysis of extracts from various cell lines using TRAF6 (D21G3) Rabbit mAb.
Flow cytometric analysis of Raji cells, using TRAF1 (45D3) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).
TRAFs (TNF receptor-associated factors) are a family of multifunctional adaptor proteins that bind to surface receptors and recruit additional proteins to form multiprotein signaling complexes capable of promoting cellular responses (1-3). Members of the TRAF family share a common carboxy-terminal "TRAF domain", which mediates interactions with associated proteins; many also contain amino-terminal Zinc/RING finger motifs. The first TRAFs identified, TRAF1 and TRAF2, were found by virtue of their interactions with the cytoplasmic domain of TNF-receptor 2 (TNFRII) (4). The six known TRAFs (TRAF1-6) act as adaptor proteins for a wide range of cell surface receptors and participate in the regulation of cell survival, proliferation, differentiation, and stress responses.
While TRAF2 was originally described through its interaction with TNFRII, it has since been shown to interact with other surface receptors including CD27, CD30, CD40, 4-1BB, Ox40, HVEM/ATAR, and LMP-1 (1-3). TRAF2 also associates with a large number of intracellular proteins, including TRADD, FADD, I-TRAF/TANK, TRIP, A20, c-IAP1 and 2, Casper, RIP, and NIK, which help to regulate cell survival. Dominant negative and knockout studies have shown that TRAF2 plays an important role in TNF-mediated activation of NF-κB and the MAPK/JNK kinase pathway (5-7).
TRAF6 plays a critical role in innate and adaptive immunity, bone metabolism, and development of certain tissues including the nervous system (8). TRAF6 deficiency results in osteopetrosis and defective IL-1, CD40, and LPS signaling (9) as well as defects in neuronal development (10). Unlike other TRAF family members that mediate signaling through TNF, TRAF6 has unique binding activities (11) that result in signaling responses from the interleukin-1 receptor (IL-1R) (12), toll-like receptor (13,14), CD (15), RANK (16,17), and p75 neurotrophin receptor (18). TRAF6 associates directly with CD40 and RANK, and indirectly with IL-1R/TLR through IRAK (13). This leads to activation of NF-κB and MAP kinase signaling pathways through downstream association with the TAB/TAK-1 complex (19). TRAF6 also activates Src family nonreceptor tyrosine kinases leading to Akt activation (20).
- Arch, R.H. et al. (1998) Genes Dev 12, 2821-30.
- Chung, J.Y. et al. (2002) J Cell Sci 115, 679-88.
- Bradley, J.R. and Pober, J.S. (2001) Oncogene 20, 6482-91.
- Rothe, M. et al. (1994) Cell 78, 681-92.
- Yeh, W.C. et al. (1997) Immunity 7, 715-25.
- Reinhard, C. et al. (1997) EMBO J 16, 1080-92.
- Rothe, M. et al. (1995) Science 269, 1424-7.
- Wu, H. and Arron, J.R. (2003) Bioessays 25, 1096-105.
- Lomaga, M.A. et al. (1999) Genes Dev 13, 1015-24.
- Lomaga, M.A. et al. (2000) J Neurosci 20, 7384-93.
- Ye, H. et al. (2002) Nature 418, 443-7.
- Cao, Z. et al. (1996) Nature 383, 443-6.
- Muzio, M. et al. (1997) Science 278, 1612-5.
- Medzhitov, R. et al. (1998) Mol Cell 2, 253-8.
- Ishida, T. et al. (1996) J Biol Chem 271, 28745-8.
- Darnay, B.G. et al. (1998) J Biol Chem 273, 20551-5.
- Wong, B.R. et al. (1998) J Biol Chem 273, 28355-9.
- Khursigara, G. et al. (1999) J Biol Chem 274, 2597-600.
- Ninomiya-Tsuji, J. et al. (1999) Nature 398, 252-6.
- Wong, B.R. et al. (1999) Mol Cell 4, 1041-9.
DRAQ5 is a registered trademark of Biostatus Limited.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.